Table 1.

Clinical characteristics and laboratory findings in patients with COVID-19.

	Wuhan No.1	Jinyintan	Total	Reference range
Gender(M/F)	11/6	10/15	21/21
Age (years old)	68.6 ± 12.7	52.28 ± 15.57	58.66 ± 16.48
Underlying diseases
hypertension	0	2	2
hyperuricemia	0	1	1
No potential comorbidities	17	22	39
Disease Severity
mild disease	0	1	1
moderate disease	1	21	22
severe disease	15	3	18
critical disease	1	0	1
Hospitalization days1
<30 days	2	0	2
30∼60 days	14	12	27
>60 days	1	13	13
Blood routine
Leukocyte (×109/L)	7.01 ± 0.58	5.49 ± 0.32	6.13 ± 0.32	3.50-9.50
Neutrophils (×109/L)	4.43 ± 0.63	3.05 ± 0.23	3.63 ± 0.31	1.80-6.30
Lymphocytes (×109/L)	1.58 ± 0.21	1.85 ± 0.12	1.74 ± 0.11	1.10-3.20
Blood chemistry
TBIL (μmol/L)	ND	10.9 ± 3.5	NA	1.71-21
Albumin (g/L)	36.06 ± 8.11	39.8 ± 3.71	38.46 ± 5.87	40–55
Globulin (g/L)	28.00 ± 6.16	27.08 ± 2.55	27.44 ± 4.28	20–40
ALT (IU/L)	28.7 ± 3.6	29.4 ± 4.3	29.1 ± 2.9	7–45
AST (IU/L)	24.3 ± 2.0	27.3 ± 2.5	26.1 ± 1.7	13–35
Creatinine (μmol/L)	70.4 ± 5.6	60.3 ± 4.1	64.5 ± 3.4	44–97
BUN (mmol/L)	5.7 ± 0.9	4.5 ± 0.2	5.0 ± 0.4	1.8-7.3
Inflammation parameters
CRP (mg/L)	17.38 ± 24.92	1.58 ± 2.03	7.75 ± 17.21	≤5
IL-6 (pg/ml)	9.50 ± 10.67	6.74 ± 2.53	7.66 ± 6.46	≤5
Treatment
antiviral2	17	0
antibiotics3	16	1

¹The infection history for patients in Jingyintan Hospital cohort study was over 30 days.

²Patients were treated with Arbidol, Oseltamivir, Kaletra, or Hydroxychloroquine.

³Patients were treated with Meropenem, Moxifloxacin, Tegafycline or Azithromycin.

Abbreviation: NLR, neutrophil-to-lymphocyte ratio; TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CRP, C-reactive protein; IL-6, interleukin-6; ND, not done; NA, not available